Health TrialsbyHealthPanel

Continuous Adductor Canal Block (CACB) Combined With İnfiltration Between the Popliteal Artery and Capsule of the Knee (iPACK) Block vs Continuous Adductor Canal Block Alone After Total Knee Arthroplasty

ConditionsTotal Knee ArthroplastyPostoperative Pain
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBaşakşehir Çam & Sakura City Hospital

About this trial

This study compares the effects of adding an infiltration between the popliteal artery and capsule of the knee (iPACK) block to a continuous adductor canal block (CACB) versus continuous adductor canal block alone on postoperative analgesia, opioid consumption, early mobilization, and length of hospital stay in patients undergoing total knee arthroplasty. This is a prospective, randomized, double-blind study with 54 patients allocated 1:1 into two groups.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients of either sex

Aged 18 to 75 years

American Society of Anesthesiologists (ASA) physical status I, II, or III

Voluntary participation

Disqualifiers

ASA physical status IV or V

Patients who decline to participate

Pediatric patients

Active infection at the block site

Trial design

Design model

Parallel

Treatments tested in this trial

  • IPACK block

    Procedure/Surgery

    Single injection of 0.25% bupivacaine 20 mL between the popliteal artery and posterior knee capsule, performed under ultrasound guidance

  • Continuous adductor canal block (CACB)

    Procedure/Surgery

    Perineural catheter placement in the adductor canal with PCA-delivered 0.1% bupivacaine (5-7 mL basal rate, 5 mL bolus, 30-min lockout) for 24 hours postoperatively

Treatment groups

54 Participants
are divided into 2 treatment groups
Group A: Group 1 (CACB + iPACK)Experimental treatment 2 interventions
Group B: Group 2 (CACB Alone)Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Postoperative Pain Score (Numeric Rating Scale)

Pain intensity assessed using the Numeric Rating Scale (NRS, 0-10; 0 = no pain, 10 = worst pain imaginable)

Time frame
Baseline and postoperative hours 1, 3, 6, 12, and 24

Secondary outcomes

1

Total Opioid Consumption

Total rescue analgesic (tramadol) consumption via intravenous (IV) administration

Time frame
Postoperative 24 hours
2

Total Local Anesthetic Consumption

Total bupivacaine consumed via patient-controlled analgesia (PCA) pump

Time frame
Postoperative 24 hours
3

Time to First Mobilization

Time to first unassisted ambulation/movement, assessed via the Timed Up and Go (TUG) test

Time frame
Postoperative 24 hours
4

Length of Hospital Stay

Number of days from surgery to discharge

Time frame
From surgery to discharge (up to approximately 1 week)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Başakşehir Çam & Sakura City Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: